FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy By Ogkologos - July 1, 2026 11 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CADENZA study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC High HPV Vaccination Coverage in England Associated with a Substantial Reduction in Cervical Cancer Mortality MOST POPULAR FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma February 28, 2024 Can Eating Grilled or Charred Foods Cause Cancer? January 10, 2023 Female Representation at the Top of the Oncology Field Has Hit... October 20, 2021 Elderly Woman Seeks Trick-Or-Treaters Who Surprised Her With Gifts The Day... November 12, 2021 Load more HOT NEWS Mammograms Can Detect COVID-19 Vaccination Swelling, Causing Cancer Scares Imetelstat Shows Durable Transfusion Independence and Disease-Modifying Activity in Heavily Transfused... The Combination of Nivolumab and Cabozantinib Provides a New First-Line Treatment... Insights Into the Biology of Response and Resistance to MAPK Pathway...
